^
    Back
    Association details:
    Biomarker:KPNA3 underexpression
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Cancer
    Title:

    KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition

    Excerpt:
    Moreover, retrospective analysis revealed that HCC patients with low KPNA3 expression had remarkably longer survival after sorafenib treatment.... Targeting KPNA3 may also contribute to resolving sorafenib resistance in HCC.
    DOI:
    10.7150/jca.31448